LTP and memory impairment caused by extracellular Aβ and Tau oligomers is APP-dependent.
Daniela PuzzoRoberto PiacentiniMauro FáWalter GulisanoDomenica D Li PumaAgnes StaniszewskiHong ZhangMaria Rosaria TropeaSara CoccoAgostino PalmeriPaul FraserLuciano D'AdamioClaudio GrassiOttavio ArancioPublished in: eLife (2017)
The concurrent application of subtoxic doses of soluble oligomeric forms of human amyloid-beta (oAβ) and Tau (oTau) proteins impairs memory and its electrophysiological surrogate long-term potentiation (LTP), effects that may be mediated by intra-neuronal oligomers uptake. Intrigued by these findings, we investigated whether oAβ and oTau share a common mechanism when they impair memory and LTP in mice. We found that as already shown for oAβ, also oTau can bind to amyloid precursor protein (APP). Moreover, efficient intra-neuronal uptake of oAβ and oTau requires expression of APP. Finally, the toxic effect of both extracellular oAβ and oTau on memory and LTP is dependent upon APP since APP-KO mice were resistant to oAβ- and oTau-induced defects in spatial/associative memory and LTP. Thus, APP might serve as a common therapeutic target against Alzheimer's Disease (AD) and a host of other neurodegenerative diseases characterized by abnormal levels of Aβ and/or Tau.
Keyphrases
- knee osteoarthritis
- working memory
- cerebrospinal fluid
- endothelial cells
- poor prognosis
- binding protein
- high glucose
- type diabetes
- oxidative stress
- squamous cell carcinoma
- radiation therapy
- mass spectrometry
- skeletal muscle
- cerebral ischemia
- locally advanced
- rectal cancer
- protein protein
- wild type
- atomic force microscopy
- mild cognitive impairment
- induced pluripotent stem cells